Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted 15 February, 2013 and appeared in  Children & TeensPractice MgmtNeuropathyIssue 664

Routine Screening for DPN in Children Needs to be Mandatory

Study calls for clinical guidelines for detecting DPN (diabetic peripheral neuropathy) in young patients….

Advertisement

The researchers reported that 26% of 151 children with Type 1 diabetes, aged 8 to 21 years, had a positive screening test for DPN.

This included six (75%) of eight patients at high-risk for DPN -- defined as age 13 years or older, diabetes duration of at least 5 years, and a HbA1c level of 10% or higher on two of the previous four measurements.

But 33 (23%) of the 143 patients who did not meet these risk criteria also had a positive screening test for DPN, which included a modified version of the Michigan Neuropathy Screening Inventory, a foot inspection, ankle reflex testing, monofilament (10 g) examination, and tuning fork testing. Follow-up with a pediatric neurologist confirmed DPN in five (62.5%) of the high-risk and 11 (46.0%) of the low-risk patients.

The average age of patients with confirmed DPN was 16.2 years. Although the average HbA1c was 8.7%, seven patients had a level equal to or below 8%. Average duration of diabetes in the DPN group was 6.4 years, but two patients had been diagnosed with diabetes within the past year.

Indeed, there was no significant correlation between diagnosis of DPN and patient age, duration of diabetes, HbA1c or cholesterol level, or height at puberty, although the researchers say this may be due to sample size or the cross-sectional study design.

This study highlights that DPN can occur in youth at any age and at any time from the onset of diagnosis.

Researchers added that, "These data raise our awareness of DPN in youth and challenge us to incorporate routine screening in practice as supported by research done outside of the US."

Diabetes Research and Clinical Practice, Feb 2013

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 15 February, 2013 and appeared in  Children & TeensPractice MgmtNeuropathyIssue 664

Past five issues: Issue 744 | Diabetes Clinical Mastery Series Issue 203 | Issue 743 | Diabetes Clinical Mastery Series Issue 202 | SGLT-2 Inhibitors Special Edition August 2014 |

2014 Most Popular Articles:

Low-carb Diet Recommended for Type 1 and 2 Diabetes Patients
Posted August 01, 2014
New Combination of Diabetes Drugs Have Synergistic Effect
Posted August 08, 2014
FDA Approves J&J's Invokamet Combo (SGLT-2 + Metformin)
Posted August 15, 2014
New Encapsulated Beta-Cell Replacement Therapy for Type 1 Diabetes
Posted August 08, 2014
Diabetic Neuropathy Improved with Vegan Diet
Posted August 22, 2014
During Prolonged Low-Intensity Exercise, Caffeine Alters Blood Glucose
Posted August 15, 2014
CDC: 40% of American Adults Will Develop Diabetes
Posted August 22, 2014
SGLT2 Inhibitor Empagliflozin Wins FDA OK
Posted August 08, 2014
Early Insulin Delays Diabetes But Are There Negative Consequences?
Posted August 15, 2014
Peripheral Neuropathy Associated with CV Disease and Stroke in Type 2 Diabetes Patients
Posted August 15, 2014


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Bernstein | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
When Afrezza is available, will you prescribe it immediately or wait until it has been on the market for a while?
CME/CE of the Week
William Tamborlane, MD, FAAP, FACE

Category: General Diabetes
Credits:
 .75
Search Articles On Diabetes In Control